ABSTRACT
Introduction: The COVID-19 pandemic has a profound impact on all aspects of the lives of societies in the world. Quality of life is a measure that can express a person's well-being in a pandemic situation. There is very less information about the impact of COVID-19 pandemic on the quality of life. Thus, the objective is to assess the impact of COVID-19 pandemic on quality of life among the employed population and to study the change in lifestyle related factors contributing to quality of life. Methodology: Cross sectional web-based study was conducted from December 2020 - May 2021 among ≥18 years of study participants. Convenient sampling method was used. Data analysis was done using Epi info software 7.2.2 version. Results: A total 252 study participants completed the study. The impact of COVID-19 pandemic was severe on physical domain 114(43.51%) and on psychological domain 20(7.63%). Overall impact of COVID-19 pandemic on quality of life was moderate 136(51.91%). 234(89.31%) participants responded that there was excellent change in lifestyle related practices. Conclusion: COVID-19 pandemic had overall moderate impact on quality of life in our study subjects, along with excellent change in lifestyle related practices. These findings would need to be verified in larger population. © 2022 University of Stockholm. All rights reserved.
ABSTRACT
Introduction: Globally COVID-19 pandemic impacted on all dimensions of the lives in the world. Quality of lifemeasures person’s well-being. Very less information was available about the influence of COVID-19 pandemic onqualityoflife.Thus,objectivewastoassessimpactandchangeinlifestylerelatedfactorscontributingtoqualityoflife among employedpopulationduetoCOVID-19pandemic. Methodology:Webbasedcrosssectionalstudywasconductedamong>18yearsofstudyparticipants.Convenientsa mplingmethodwasused. DataanalysiswasdoneusingEpi infosoftware7.2.2version. Results: A total 252 study participants completed the study. COVID-19 pandemic impact was severe on physicaldomain 114(43.51%) and on psychological domain 20(7.63%). Over all the effect of pandemic on quality of lifewas moderate 136(51.91%). 234(89.31%) participants responded that there was excellent change in lifestylerelatedpractices. Conclusion:COVID-19pandemichadmoderatelyaffectedqualityoflifeinourstudysubjects,alongwithexcellentchangeinlifestylerelate dpractices. Studies in huge population will be requiredtoverify these findings.
ABSTRACT
Background/Aims Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undoubtedly changed the course of the pandemic and lessened hospital admissions and death as a result of the aforementioned virus. Reactive arthritis has been reported with other vaccinations, for example influenza, and now it seems patients are presenting with similar symptoms post SARS-CoV-2 vaccination, the first human mRNA vaccine to be used against a virus. There are occasional case reports in the literature of patients developing various rheumatological conditions post COVID-19 vaccination including reactive arthritis and polymyalgia rheumatica. Currently the Summary of Product Characteristics (SmPC) for Pfizer BioNTech, Moderna and AstraZenica vaccinations only list myalgia and arthralgia as side effects in the musculoskeletal and connective tissue disorders section. Our aim was to collect data in a prospective manner on patients who presented to clinic with a new rheumatological condition which was believed to have been triggered by receiving a COVID-19 vaccination and their progress was followed over time. Methods Data have been collected prospectively from patients who have presented to the West Suffolk NHS Foundation Trust rheumatology department with symptoms which are thought to be attributable to COVID-19 vaccination over the last five months. Results Nineteen patients had a new inflammatory condition that appeared to have been triggered by the COVID-19 vaccination. The mean age of onset of symptoms is 65.2 years (range 22-85 years) with the mean number of days between vaccine and symptom onset of 9.6 days. 89% presented within 14 days of vaccination. Eleven patients received the Pfizer BioNTech vaccine and 6 the AstraZeneca vaccine. Seven patients presented after their first vaccine and seven after their second. Three had symptoms after both. The most common presentation was a small joint polyarthritis (8 patients) and polymyalgia rheumatica type symptoms (5). All but one were seronegative. So far, outcomes have varied between self-resolution or conservative management (6 patients), short- and long-term prednisolone requirement (6) and initiation of disease modifying anti-rheumatic drugs (5). Conclusion The emergence of post-COVID-19 vaccine inflammatory arthritis appears to be a new condition which rheumatologists will be required to treat. With the introduction of booster vaccinations and third doses this phenomenon is likely to be seen in clinic for the foreseeable future. Further data are required in order to guide best treatment options and enable better prognostic indicators.